Elicera Therapeutics AB (DE:8E8)

FRANKFURT:8E8

8E8

Elicera Therapeutics AB

RESEARCH TOOLSreports

Elicera Therapeutics AB (8E8) Price & Analysis

Compare

0 Followers

8E8 Stock Chart & Stats

€0.47

€0.03(20.86%)

At close: Jan 08 4:00 PM EST

€0.47

€0.03(20.86%)

Day’s Range― - ―

52-Week Range€0.18 - €0.69

Previous CloseN/A

Volume0.00

Average Volume (3M)0.00

Market Cap

€24.76M

Enterprise Value€245.98M

Total Cash (Recent Filing)€24.85M

Total Debt (Recent Filing)€0.00

Price to Earnings (P/E)―

Beta0.08

Next Earnings

Apr 28, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.01

Shares Outstanding48,535,545

10 Day Avg. Volume0

30 Day Avg. Volume0

Financial Highlights & Ratios

PEG Ratio0.54

Price to Book (P/B)10.19

Price to Sales (P/S)0.00

P/FCF Ratio-11.04

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)-0.05

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Next-generation Immuno-oncology R&DElicera’s focus on CAR‑T and oncolytic virus approaches aligns with structural growth in immuno‑oncology. These modalities carry high technical barriers and can create platform value and durable differentiation if clinical progress advances toward regulatory validation and commercialization.

Conservative Capital Structure (zero Debt)Zero debt materially reduces insolvency risk and preserves strategic flexibility for an R&D‑stage biotech. A debt‑free balance sheet improves options for milestone financing, licensing deals or orderly equity raises, supporting longer runway and lower fixed financial burden.

Strong Gross Profit When Revenue ExistedWhen revenues were recorded, gross margins were high, indicating product/service economics that can scale efficiently. If the company translates R&D into commercial offerings, the underlying margin structure supports durable profitability once fixed R&D and SG&A are absorbed.

Bears Say

Persistent Operating Losses And Negative Cash FlowConsistent operating losses and negative operating/free cash flow indicate ongoing cash burn without self‑funding. Over 2–6 months this structural cash gap implies reliance on external financing, elevating dilution risk and potentially constraining development timelines if capital access tightens.

Revenue Volatility And Zero Revenue In 2025The collapse to zero reported revenue in 2025 highlights weak commercial visibility and inconsistent revenue generation. Structurally, this undermines forecasting, reduces predictability of cash inflows, and raises the stakes on successful clinical milestones to restore sustainable revenue streams.

Declining Equity And Value Dilution RiskMaterial equity erosion over several years shrinks the balance sheet buffer against shocks and limits internal financing capacity. This structural weakening increases dependence on external capital raises, heightening dilution risk for shareholders and reducing financial flexibility over the medium term.

8E8 FAQ

What was Elicera Therapeutics AB’s price range in the past 12 months?

Elicera Therapeutics AB lowest stock price was €0.18 and its highest was €0.69 in the past 12 months.

What is Elicera Therapeutics AB’s market cap?

Elicera Therapeutics AB’s market cap is €24.76M.

When is Elicera Therapeutics AB’s upcoming earnings report date?

Elicera Therapeutics AB’s upcoming earnings report date is Apr 28, 2026 which is in 30 days.

How were Elicera Therapeutics AB’s earnings last quarter?

Elicera Therapeutics AB released its earnings results on Feb 13, 2026. The company reported -€0.013 earnings per share for the quarter, missing the consensus estimate of N/A by -€0.013.

Is Elicera Therapeutics AB overvalued?

According to Wall Street analysts Elicera Therapeutics AB’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Elicera Therapeutics AB pay dividends?

Elicera Therapeutics AB does not currently pay dividends.

What is Elicera Therapeutics AB’s EPS estimate?

Elicera Therapeutics AB’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Elicera Therapeutics AB have?

Elicera Therapeutics AB has 48,535,545 shares outstanding.

What happened to Elicera Therapeutics AB’s price movement after its last earnings report?

Elicera Therapeutics AB reported an EPS of -€0.013 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -4.636%.

Which hedge fund is a major shareholder of Elicera Therapeutics AB?

Currently, no hedge funds are holding shares in DE:8E8

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Elicera Therapeutics AB

Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio of products in pipeline includes ELC-100, a Phase I/II drug candidate for neuroendocrine tumors indications; ELC-201, a preclinical drug candidate; ELC-301, a CAR T-cell therapy for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a preclinical drug candidate glioblastoma multiforme (brain tumor) indications. It also develops iTANK, a technology platform used to optimize the effect of all CAR T-cell therapies under the development and activate killer T-cells against cancer. The company was founded in 2014 and is based in Göteborg, Sweden.